

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Re application of: Mukherjee et al.

Application No. 10/019,833

Filed: November 20, 2002

Confirmation No. 8664

For: UTEROGLOBIN IN THE TREATMENT
OF IGA MEDIATED AUTOIMMUNE
DISORDERS

Examiner: David A. Saunders, Ph.D.

Art Unit: 1646

Attorney Reference No. 4239-61375-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)

Date Mailed November 1, 2004

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

TRANSMITTAL LETTER

Enclosed for filing in the application referenced above are the following:


- ☒ Supplemental Information Disclosure Statement
- ☒ Form 1449 and copy of the reference cited thereon
- ☒ The Director is hereby authorized to charge any additional fees that may be required, or credit over-payment, to Deposit Account No. 02-4550. A copy of this sheet is enclosed.
- ☒ Please return the enclosed postcard to confirm that the items listed above have been received.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By Gillian L. Bunker
Gillian L. Bunker, Ph.D.
Registration No. 47,461

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391
Facsimile: (503) 228-9446
cc: Docketing



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Mukherjee et al.

Application No. 10/019,833

Filed: November 20, 2002

Confirmation No. 8664

For: UTEROGLOBIN IN THE TREATMENT OF
IGA MEDIATED AUTOIMMUNE
DISORDERS

Examiner: David A. Saunders, Ph.D.

Art Unit: 1646

Attorney Reference No. 4239-61375-01

CERTIFICATE OF MAILING

I hereby certify that this paper and the documents referred to as being attached or enclosed herewith are being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: MAIL STOP AMENDMENT, COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450 on the date shown below.

Agent
for Applicant(s)Date Mailed November 1, 2004

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
PURSUANT TO 37 C.F.R. § 1.97(e)(1)**

MAIL STOP AMENDMENT
COMMISSIONER FOR PATENTS
P.O. BOX 1450
ALEXANDRIA, VA 22313-1450

Listed on the accompanying form PTO-1449 and enclosed herewith is an English-language document. Applicants respectfully request that this document be listed as a reference cited on the issued patent.

This statement is provided in compliance with 37 C.F.R. § 1.97(e)(1). The undersigned hereby states that the reference listed in the IDS filed herewith was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the statement. As a result, no fee should be required to file this IDS.

The filing of this IDS shall not be construed to be an admission that the information cited in the statement is, or is considered to be, prior art or otherwise material to patentability as defined in 37 C.F.R. §1.56.


Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By

Gillian L. Bunker, Ph.D.
Registration No. 47,461

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 226-7391 / Facsimile: (503) 228-9446



**SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

Attorney Docket Number	4239-61375-01
Application Number	10/019,833
Filing Date	November 20, 2002
First Named Inventor	Mukherjee
Art Unit	1646
Examiner Name	David A. Saunders, Ph.D.

FOREIGN PATENT DOCUMENTS

Examiner's Initials*	Cite No. (optional)	Country	Number	Publication Date	Name of Applicant or Patentee
		WIPO/PCT	WO 01/32677	10 May 2001	Human Genome Sciences, Inc.

**EXAMINER
SIGNATURE:**

**DATE
CONSIDERED:**

* Examiner: Initial if reference considered, whether or not in conformance with MPEP 609. Draw line through cite if not in conformance and not considered. Include copy of this form with next communication to applicant.